Introduction
Apelin is an endogenous peptide hormone, which exerts potent positive inotropic activity 1,2 through binding to its cognitive receptor APJ/ Apelin receptor/Aplnr. APJ is a G-protein coupled receptor which shares significant homology with the angiotensin II type 1 receptor (AT1R). 3, 4 Apelin peptide exerts load-independent positive inotropy and increases coronary blood flow by vascular dilation, thereby providing beneficial effects in failing hearts. 5, 6 The endogenous Apelin-APJ axis maintains heart contractility and is cardioprotective under conditions of aging, exercise, and pressure overload; as evidenced by the observation that mouse knockout of Apelin or APJ show reduced contractile functions and enhanced cardiac damage in such conditions. 7, 8 In addition, the Apelin-APJ system negatively regulates angiotensin II (Ang II)-AT1R signalling through heterodimeric interaction of APJ and AT1R in atherosclerosis or upregulation of angiotensin-converting enzyme 2 (ACE2) expression in pressure overload heart failure. Elabela/Toddler/Apela (ELA, www.elabela.com) has been recently identified as a second endogenous ligand for the APJ/Apelin receptor/ Aplnr. ELA comprises a conserved C-terminal portion, which is cleaved from a 54 amino acid precursor to produce a mature peptide hormone of 32 amino acids. 11 During zebrafish embryogenesis, ELA mediates endoderm differentiation and cell migration and thereby contributes to early cardiac development. 11, 12 Since APJ-deficient zebrafish shares the same phenotype as ELA mutants during embryogenesis, ELA was identified as the cognate peptide ligand for APJ receptor. [11] [12] [13] Several recent studies have shown that ELA peptide can activate mammalian APJ, regulates water balance, and is inotropic for contractility of the isolated ex vivo heart. [14] [15] [16] Recently, ELA has been implicated in the self-renewal of human embryonic stem cells in an autocrine manner, which might be mediated through an alternate cell-surface receptor, distinct from APJ. 17 Although in the adult heart Apelin had been thought as the only ligand of APJ, the discovery of ELA begs the question whether ELA also plays a role in pathogenesis of cardiovascular diseases.
In this study, we show beneficial effects of ELA peptide (32 amino acids) on the pathology of pressure overload-induced heart failure in mice. We also demonstrate that endogenous APJ is an essential receptor for ELA to exert cardioprotective effects in failing hearts and that ELA antagonizes Ang II-induced hypertension and cardiac damage in mice.
Methods

Mice
C57BL/6J and C57BL/6N wild-type mice were purchased from Japan SLC and maintained at the animal facilities of Akita University Graduate School of Medicine. APJ knockout mice were generated and maintained as described previously. 18 All animal experiments conformed to the Guide for the Care and Use of Laboratory Animals, Eighth Edition, updated by the US National Research Council Committee in 2011, and approvals of the experiments were granted by the ethics review board of Akita University.
Pharmacological intervention
The 32 amino-acid long human ELA peptide with the following primary sequence (NH 2 -QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP-COOH) comprising an intra-molecular disulfide bond was produced synthetically at >98% purity (BEX) and dialyzed twice into PBS. For ELA treatment, wild-type or APJ KO male mice at the age of 3-month old were subcutaneously infused with either saline or the ELA peptide at 1 mg/kg/day for 2 weeks by osmotic mini-pumps (Alzet model 1002, Alza Corp., Mountain View, CA, USA) after TAC surgery. For Ang II and ELA treatment, wild-type male mice at the age of 3-month old were subcutaneously infused with Ang II (Sigma-Aldrich, St. Louis, MO, USA), ELA or its combination by using osmotic pump for 2 weeks. The treatment dose of peptide was 1 mg/kg/day. For Apelin treatment, wild-type mice at the age of 3-months old were subcutaneously infused with 1 mg/kg/ day of Apelin-13 (BEX) using osmotic pump for 2 weeks. Two weeks after treatment, echocardiography was performed and mice sacrificed by cervical dislocation.
Transverse aortic constriction (TAC)
Three-month old wild-type mice or APJ KO mice were subjected to pressure overload by transverse aortic constriction (TAC) as previously described. 7 Briefly, mice were anesthetized via intraperitoneal injection of ketamine (100 mg/kg) and xylazine (20 mg/kg), and a longitudinal incision was made in the proximal portion of sternum. The aortic arch was ligated with an overlying 27-gauge needle by 7-0 silk. The needle was immediately removed leaving a discrete region of constriction. The sham-treated group underwent a similar procedure without ligation. Echocardiography was performed 2 weeks after TAC or sham surgery and mice were then sacrificed by cervical dislocation.
Echocardiography and blood pressure measurements
Echocardiographic measurements were performed as previously described. 7 Briefly, after mice were anesthetized with isoflurane (1%)/ oxygen, echocardiography was performed using Vevo770 equipped with a 30-MHz linear transducer. Fractional shortening (FS) was calculated as follows: FS = [(LVEDD -LVESD)/LVEDD] Â 100. M-mode images were obtained for the measurement of wall thickness and chamber dimensions with the use of the leading-edge convention adapted by the American Society of Echocardiography. Blood pressures were measured in conscious mice by a programmable sphygmomanometer (BP-200, Softron, Tokyo, Japan) using the tail cuff method after 5 days of daily training, as described previously. 7 
Histology
Heart tissues were fixed with 4% formalin and embedded in paraffin. Five lm thick sections were prepared and stained with Hematoxylin & Eosin or Masson & Trichrome.
Quantitative real-time PCR
RNA was extracted using TRIzol reagent (Invitrogen, Waltham, MA, USA) and cDNA synthesized using the PrimeScript RT reagent kit (TAKARA, Berkeley, CA, USA). Sequences of the forward and reverse primers of the genes studied are shown in Supplementary material online, Table S1 . Real-time PCR was run in 96-well plates using a SYBR Premix ExTaq II (TAKARA) according to the instructions of the manufacturer. Relative gene expression levels were quantified by using the Thermal Cycler Dice Real Time System II software (TAKARA).
Western blotting
Heart protein was extracted using a TNE lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP40, protease inhibitor (complete Mini, Roche, Indianapolis, IN, USA), 100 mM NaF, 2 mM Na 3 VO 4 ), and Microsmash (MS-100R, TOMY, Cologne, Germany). After sonication and denature with LDS sample buffer (Invitrogen) at 70 C, proteins were electrophoresed on NuPAGE bis-tris precast gels (Invitrogen) and transferred to nitrocellulose membranes (0.45mm pore, Invitrogen). Anti-ACE2 antibody was used as described, 19 
Primary cardiomyocyte cultures
Primary cardiomyocytes were isolated from prenatal mouse hearts of wild type mice as described previously. 10 Briefly, prenatal mice (E17. 5) were removed from pregnant mice euthanized by cervical dislocation, prenatal mouse hearts were harvested and rapidly minced into 3 or 4 pieces in MSS buffer (30 . The cells were observed by using a BIOREVO microscope (BZ9000, Keyence) and analyzed using the BZII analyzer software (Keyence, Osaka, Japan).
Statistical analyses
Data are presented as mean values ± SEM. Statistical significance between two experimental groups was determined using Student's twotailed t-test. Comparisons of parameters among more than three groups were analyzed by one-way ANOVA, followed by Turkey's post-hoc test. When a comparison is done for groups with two factor levels, two-way ANOVA with Sidak's correction for post-hoc multiple comparisons were used. P < 0.05 was considered significant.
Results
Injected ELA rescues cardiac dysfunction and hypertrophy in mice under TAC pressure overload
To examine the functional role of ELA in the heart, we first conducted continuous infusions of ELA peptide into wild type mice (C57/BL6N) under pressure overload induced by TAC (transverse aortic constriction) surgery. After 2 weeks of TAC, % fractional shortening (%FS) was significantly decreased in the vehicle treatment group, while %FS was preserved in ELA-treated mice ( Figure 1A -C). Heart weight to body weight ratio (HW/BW) was also significantly decreased in the ELA treated group as compared with the vehicle-treated control cohort ( Figure 1D ,E). Similarly, ELA treatment significantly suppressed the increased expression of mRNA associated with cardiac hypertrophy, such as brain natriuretic peptide (BNP), atrial natriuretic factor (ANF), and b-myosin heavy chain (b-Myhc) ( Figure 1F -H), in the TAC mice.
Histological analysis further revealed that ELA treatment reduced the area of cardiac fibrosis in the interstitial space and perivascular region in the hearts of TAC mice (Figure 2A,B) . Consistently, while the expression of the pro-fibrotic genes TGFb2 (Tgfb2), Latent TGFb binding protein 2 (Ltbp2), Periostin (Postn), and Collagen 8a (Col8a) were increased in the hearts of vehicle-treated mice with TAC, ELA treatment markedly downregulated the expression of those pro-fibrotic genes ( Figure 2C-F) . These results indicate that exogenous ELA peptide treatment can protect mice from pressure overload-induced cardiac dysfunction, hypertrophy, and fibrosis.
ELA downregulates ACE expression in the hearts under TAC
Enhanced activity of renin-angiotensin system (RAS) is a key pathway involved in the progression of heart failure in mice with TAC. 20 Since we had previously shown that Apelin upregulates ACE2 expression in the heart, 10 we examined ACE2 expression in ELA-treated TAC mice.
Levels of ACE2 showed a trend for increased, albeit not significantly increased, expression in ELA-treated TAC mice ( Figure 2G ). However, ELA treatment downregulated the increased expression of ACE ( Figure  2H ) resulting in a reduced ACE to ACE2 ratio in TAC mice ( Figure 2I ). Angiotensinogen mRNA levels appeared unaffected by ELA treatment ( Figure 2J ). On the other hand, ELA treatment did not significantly affect mRNA expression of APJ and ELA ( Figure 2K ,L). These data suggest that ELA treatment can reduce RAS activity under pathogenic TAC conditions.
ELA exerts its cardioprotective effects in an APJ-dependent manner
While ELA has been identified as a second endogenous ligand for the APJ receptor, it was recently suggested that an alternate receptor for ELA exists, and is implicated in the self-renewal of human embryonic stem cells. 17 We thus examined whether the cardioprotective effects of ELA depend on the APJ receptor. We subjected wild type mice and APJ knockout (KO) mice ( Figure 3A ) (both on a C57/BL6J genetic background) to TAC and treated the mice with vehicle or ELA peptide by continuous infusion. After 2 weeks of TAC, loss of APJ significantly reduced cardiac hypertrophy ( Figure 3B ,C), whereas cardiac contractility was not significantly altered at this stage in the C57/BL6J background ( Figure 3D ,E), consistent with previous reports. 21, 22 On the other hand, ELA treatment did not affect heart weight and LV wall thickness in APJ knockout mice with TAC ( Figure 3B,C) , also shown by echocardiography that there were no alterations in the thickness of interventricular septum (IVS) or posterior wall dimension (PWd) ( Figure 3F ,G). In addition, the observed interstitial fibrosis in the hearts of APJ KO mice with TAC was not improved by ELA treatment ( Figure 3H) . Consistently, mRNA expressions of genes associated with hypertrophy or fibrosis were not further altered by ELA treatment in APJ KO mice under TAC ( Figure 3I ). These data indicate that ELA exerts its inhibitory effects on TACinduced cardiac hypertrophy and fibrosis in an APJ receptor-dependent manner.
Differential effects of ELA and Apelin on expression of ACE and ACE2
To address how ELA regulates ACE, we determined the mRNA expression levels of ACE and ACE2 in the hearts of C57/BL6J wild-type mice at baseline treated with either Apelin-13 or ELA peptide. Consistent with our previous data, 10 Figure 4A ) but upregulated ACE2 mRNA expression in the hearts ( Figure 4B ). By contrast, ELA treatment did not alter ACE2 mRNA expression but downregulated ACE mRNA levels ( Figure 4A,B) . Consistently, the protein expression of ACE but not ACE2 was significantly downregulated in ELA-treated hearts ( Figure 4C) . Notably, when we compared the effects of ELA and Apelin on cardiac dysfunction under TAC, there was no apparent difference between ELA and Apelin on heart function, cardiac hypertrophy and heart failure gene expressions (see Supplementary material online, Table S2 and Figure S1A ,B). Thus, ELA and Apelin differentially regulate ACE and ACE2 expressions but exert equivalent cardioprotective effects under TAC stress. Since Apelin-APJ axis activates ACE2 promoter activity, 10 we next compared the effect of ELA on ACE2 promoter activation with the Apelin effect by co-transfecting the ACE2 promoter (-252/þ103)-luciferase reporter with the APJ receptor plasmids in HEK293T cells. While
Apelin potently activated ACE2 promoter in APJ-transfected HEK293T cells as described, 10 ELA showed modest effects on ACE2 promoter activation, in which the maximal effect was approximately half of Apelin ( Figure 4D ). To clarify whether ELA transcriptionally regulate ACE expression, we further conducted ACE-promoter reporter assays with the ACE promoter (-230/þ1)-luciferase reporter and the APJ plasmids. ELA dose dependently decreased ACE promoter activity in APJtransfected HEK293T cells, whereas ELA did not affect the activity in the absence of APJ (Mock-transfected cells) ( Figure 4E ). On the other hand, Apelin did not affect ACE promoter activity consistent with previous data 10 ( Figure 4E ). Since Ang II is a potent inducer of ACE expression, [23] [24] [25] we further examined the effects of ELA on ACE expression in Ang II-treated hearts. Continuous infusion of Ang II increased both mRNA and protein levels of ACE expression in the hearts of wildtype mice ( Figure 4F,G) . To gain more mechanistic insight into the different effects of ELA and Apelin on ACE expression, we compared the effects of ELA and Apelin on activation of APJ receptor in in vitro heterologous expression system with cAMP production, receptor internalization and b-arrestin recruitment as readouts, but no apparent differences between ELA and Apelin effects were detected (see Supplementary material online, Figure S1C ). We next examined cellular signalling in the hearts treated with ELA or Apelin. Again there was no difference in phosphorylation status of Akt, ERK1/2 or p38 MAPK between ELA and Apelin-treated hearts or cardiomyocytes (see Supplementary material online, Figure S1D -G and not shown). Since Brg1-FoxM1 transcription factor complex was recently reported to upregulate ACE expression in the stressed hearts, 26 we measured the mRNA expression levels by qRT-PCR. FoxM1 but not Brg1 expression was upregulated under TAC stress, whereas ELA but not Apelin significantly downregulated FoxM1 expression in the TAC hearts ( Figure 4I and see Supplementary material online, Figure S1H) . Similarly, Ang II-induced FoxM1 mRNA expression was significantly downregulated by ELA ( Figure 4J ), while ELA did not affect Brg1 expression (see Supplementary material online, Figure S1I ). Thus, ELA transcriptionally downregulates ACE expression possibly via negative regulation of FoxM1 transcription factor in the heart.
The ELA-APJ axis antagonizes angiotensin II-induced hypertension and cardiac damage
To further address the effects of ELA on the RAS, we assessed the effects of ELA peptide on Ang II-induced cardiovascular dysfunctions. Continuous infusion of Ang II elevated, as expected, blood pressure in C57/BL6J wild-type mice, whereas co-treatment of ELA and Ang II Figure 5A-C) , indicating that ELA antagonized the vasopressor effect of Ang II. In addition, ELA suppressed Ang II-induced cardiac hypertrophy and upregulation of heart to body weight ratios ( Figure 5D,E) . Consistently, Ang IIinduced LV wall thickening was significantly downregulated by ELA treatment as shown by echocardiography ( Figure 5F ,G), whereas neither Ang II nor ELA influenced cardiac contractility as determined by %FS ( Figure  5H) . Similarly, in in vitro mouse cardiomyocytes, ELA antagonized Ang IIinduced hypertrophy and increase of ANF expression (see Supplementary material online, Figure S3A ,B). Moreover, cardiac mRNA expression of BNP, which was upregulated by Ang II, was markedly reduced in ELA-treated mice ( Figure 5I) . Finally, ELA significantly reduced Ang II-induced cardiac fibrosis and fibrotic genes expression ( Figure 5J-N) . These results demonstrate that exogenous ELA peptide can suppress Ang II-induced hypertension, cardiac hypertrophy, and fibrosis.
Discussion
In this study, we demonstrate that ELA peptide improves cardiac dysfunction, hypertrophy, and fibrosis induced by pressure overload in mice. These effects are contingent on the presence of ELA's cognate receptor, since APJ-knockout mice could not respond to ELA treatment. Unexpectedly, the ELA-APJ axis was found to down-regulate transcription of ACE, whereas it had little effects on ACE2 expression in the heart. Downregulation of ACE expression was correlated with downregulation of FoxM1 transcription factor. Moreover, we report that ELA, similar to Apelin, antagonizes Ang II-induced hypertension and cardiac damage and remodelling. We thus conclude that ELA, signalling via APJ, exhibits potent cardioprotective effects in failing hearts. ELA and Apelin, which are phylogenetically unrelated, share the same receptor APJ, and show similar effects in cell migration during zebrafish ELABELA-APJ axis protects from heart failure development 12 and in diuresis and water intake of rats in vivo. 16 It has been recently shown that ELA can competitively replace Apelin bound to rat cardiomyocytes and that the perfusion of ELA increases contractility of ex vivo isolated rat hearts in an MAPK kinase 1/2 (MEK1/2)-dependent manner. 15 The effect of ELA in the heart is thus most likely mediated through APJ. On the other hand, it has been recently suggested that ELA can function through an alternate receptor in human embryonic stem cells. 17 Our genetic study utilizing APJ-knockout mice, however, indicate that, in the stressed hearts, APJ is the key receptor for ELA to mediate cardioprotective signalling. Inotropic actions of Apelin-APJ have been reported to be mediated by protein kinase C (PKC), Na
exchanger, 1, 27, 28 and extracellular signal-regulated kinase 1/2 (ERK1/2). 29 On the other hand, ELA has been recently shown to induce cardiac contractility independently of PKC, 15 implicating that ELA and Apelin exert similar cardioprotective effects through different signalling pathways. It is known that pressure overload-induced cardiac hypertrophy leads to a mismatch between supply and requirement of blood in the heart, and results in systolic dysfunction. 30, 31 Apelin exerts vasodilatory effects via the PI3K/Akt/eNOS pathway in vascular endothelium, 32 and increased blood flow in coronary artery and vaso vasorum by Apelin has been linked to the cardioprotective response. 6, 33 A recent study reported that ELA also activates the PI3K/Akt pathway in human embryonic stem cells, 17 suggesting that ELA-induced activation of PI3K/Akt may also be operational in the cardiac endothelium. Consistently, ELA has been suggested to be vasodilatory in the vasculature of isolated rat hearts. 15 Thus, the vasodilatory effect of ELA may also contribute to the beneficial effects in pressure overloaded and Ang II-challenged hearts. The Apelin-APJ system plays a counter-regulatory role to the RAS. Several signalling mechanisms are known to be critical for this antagonism, 9, 10, 34 including oligomeric interaction of AT1R and APJ to inhibit the activation of AT1R. We have previously shown that endogenous Apelin upregulates ACE2 levels transcriptionally and thereby decreases Ang II levels in the hearts. 10 However, our current results indicate that ELA peptide treatment has little effects on ACE2 expression in the heart, whereas ELA downregulates ACE transcription. Increased ratio of ACE to ACE2 leads to RAS acceleration and cardiac remodelling such as hypertrophy and fibrosis, and clinical relevance of balancing ACE/ACE2 in heart function has been reported. 35 In the stressed hearts, Ang II upregulates ACE expression levels via the p38 MAPK 23 or HIF1a/STAT3 pathways, 36 and this positive feed-forward loop results in cardiac remodelling. Brg1-FoxM1 transcription complex functions as both a transactivator and a repressor for transcription regulation, and it is recently reported to induce ACE expression by a transcription activator but suppress ACE2 expression by a repressor in the TAC-stressed hearts. 26 We found that ELA, but not Apelin, decreases TAC stress-induced upregulation of FoxM1 expression. Such differential effect of ELA on signalling but similar cardioprotective effect has been also observed in ex vivo rat heart function measurements in that ELA induces cardiac contractility independently of PKC signalling, which is distinct from Apelin's signalling. 15 The reason why ELA has no significant effects on ACE2 expression in the hearts may be explained by minor effects of ELA on the repressor activity of FoxM1 for transcription regulation. Indeed, pharmacological inhibition of transactivator activity of FoxM1 was not enough to induce ACE2 expression in the hearts. 26 Together with ELA's weak effect on activation of ACE2 promoter in vitro, the findings may implicate biased inhibitory effects of ELA on transactivator activity of FoxM1. Thus, although further studies are needed, it can be speculated that Brg1-FoxM1 transcription complex is negatively regulated by ELA through PKC-independent mechanisms, leading to downregulation of ACE expression. Despite the difference in amino acid sequence, both ELA and Apelin peptides are rich in basic residues and have similar high isoelectric points. 11 Earlier studies have shown that the C-terminal Phenylalanine (Phe) residue of Apelin-13 peptide is crucial for activation of APJ as shown by deletion-or alanine-mutant peptides, 37, 38 and that chemical modifications of C-terminal Phe of Apelin can modulate the potency of Apelin to activate APJ. 39 On the other hand, although ACE2 efficiently cleaves the C-terminus Pro-Phe bond of Apelin, the C-terminal ProPhe-Pro of ELA is resistant to cleavage by ACE2 (unpublished results). It has been recently reported that prolonged half-life of Apelin peptide by nano-liposomal encapsulation or Apelin analogues resistant to ACE2-mediated inactivation enhanced cardioprotective effects of Apelin. 40, 41 Thus, ELA and Apelin are differentially processed and hence their potency and half-lives might be different which could affect them in vivo cardioprotective effects. In summary, our results reveal that the ELA-APJ axis is protective against pressure overload-induced heart failure and antagonizes the effects of Ang II in the heart. ELA has similar beneficial roles to Apelin in heart failure but has distinct structures and regulations. Utilizing ELA peptide as a therapeutic compound could be another option to activate APJ in cardiovascular diseases. Further analyses for ELA and Apelin signalling should provide more mechanistic insights into regulation of APJ activation in cardiovascular diseases.
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